There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.
Type | HazMat fee for 500 gram (Estimated) |
Excepted Quantity | USD 0.00 |
Limited Quantity | USD 15-60 |
Inaccessible (Haz class 6.1), Domestic | USD 80+ |
Inaccessible (Haz class 6.1), International | USD 150+ |
Accessible (Haz class 3, 4, 5 or 8), Domestic | USD 100+ |
Accessible (Haz class 3, 4, 5 or 8), International | USD 200+ |
Structure of Doxazosin mesylate
CAS No.: 77883-43-3
*Storage: {[sel_prStorage]}
*Shipping: {[sel_prShipping]}
The BI-3802 was designed by Boehringer Ingelheim and could be obtained free of charge through the Boehringer Ingelheim open innovation portal opnMe.com, associated with its negative control.
Doxazosin mesylate is a selective α1-adrenergic receptor blocker, used to treat high blood pressure and urinary retention associated with benign prostatic hyperplasia (BPH).
Synonyms: UK 33274 mesylate; Doxazosin (mesylate); UK 33274-27
4.5
*For Research Use Only !
Change View
Size | Price | VIP Price | US Stock |
Global Stock |
In Stock | ||
{[ item.pr_size ]} |
Inquiry
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.discount_usd) ]} {[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} |
Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]} | Inquiry {[ item.pr_usastock ]} In Stock Inquiry - | {[ item.pr_chinastock ]} {[ item.pr_remark ]} In Stock 1-2 weeks - Inquiry - | Login | - + | Inquiry |
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
1-2weeks
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd,1,item.mem_rate,item.pr_is_large_size_no_price, item.pr_usd) ]}
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
In Stock
- +
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
CAS No. : | 77883-43-3 |
Formula : | C24H29N5O8S |
M.W : | 547.58 |
SMILES Code : | O=C(N1CCN(C2=NC(N)=C3C=C(OC)C(OC)=CC3=N2)CC1)C4OC5=CC=CC=C5OC4.CS(=O)(O)=O |
Synonyms : |
UK 33274 mesylate; Doxazosin (mesylate); UK 33274-27
|
MDL No. : | MFCD00216023 |
InChI Key : | VJECBOKJABCYMF-UHFFFAOYSA-N |
Pubchem ID : | 62978 |
GHS Pictogram: |
![]() ![]() |
Signal Word: | Danger |
Hazard Statements: | H372-H411 |
Precautionary Statements: | P260-P273-P314-P391-P501 |
Class: | 6.1 |
UN#: | 2811 |
Packing Group: | Ⅲ |
Target |
|
In Vitro:
Concentration | Treated Time | Description | References |
HL-1 cells | 17.3 μM (EC50) | 19.5 hours | PMC3514767 | |
HMVEC-L cells | 10 μM | 9 hours | Evaluate the effect of DZ-50 on migration in HMVEC-L cells, results showed DZ-50 significantly inhibited endothelial cell migration | PMC2194658 |
HUVEC cells | 10 μM | 24 hours | To assess the biocompatibility of PP@T, results showed that even at higher concentrations, the viability of HUVEC cells remained above 85%. | PMC2194658 |
DU-145 cells | 10 μM | 24 hours | Evaluate the effect of DZ-50 on apoptosis in DU-145 cells, results showed DZ-50 at 10 μM did not induce classic apoptosis within 24 hours | PMC2194658 |
PC-3 cells | 10 μM | 24 hours | To evaluate the cytotoxic effects of EPI-001 and its derivatives on PC-3 cells. Results showed EPI-001 had no significant toxicity in PC-3 cells. | PMC2194658 |
U3118shBMI1 | 5 µM | 8 days | To evaluate the effect of Doxazosin on the proliferation of U3118shBMI1 cells, results showed that Doxazosin had no significant effect on the proliferation of U3118shBMI1 cells | PMC7082224 |
U3118shScr | 5 µM | 8 days | To evaluate the effect of Doxazosin on the proliferation of U3118shScr cells, results showed that Doxazosin significantly inhibited the proliferation of U3118shScr cells | PMC7082224 |
LX-2 cells | 1, 5, 10, 20, 30, 40, 50, 60 μM | 24 hours | To evaluate the effect of Sophocarpine on TGF-β1-induced trans-differentiation of LX-2 cells. Results showed that Sophocarpine significantly inhibited the expression of TGF-β1, COL1A, Fibronectin, and TIMP1 in TGF-β1-treated LX-2 cells, indicating its antifibrotic effect. | PMC8387324 |
PC3 cells | 100 μM | 1 hour | To assess the effect of MYCi975 on MYC/MAX interaction, results showed that MYCi975 significantly disrupted the formation of MYC/MAX complex. | PMC5432519 |
In Vivo:
Administration | Dosage | Frequency | Description | References |
Nude mice | Human prostate cancer xenograft model | Oral gavage | 200 mg/kg | Once daily for 2 weeks | Evaluate the inhibitory effect of DZ-50 on prostate tumor growth, results showed DZ-50 significantly suppressed the growth of PC-3 and DU-145 xenografts | PMC2194658 |
NODSCID mice | U3118 xenograft model | Subcutaneous injection | 100 mg/kg | Daily for 16 weeks | To evaluate the effect of Doxazosin on U3118shScr and U3118shBMI1 xenograft tumors, results showed that Doxazosin significantly reduced the volume and proliferation of U3118shScr tumors, but had no significant effect on U3118shBMI1 tumors | PMC7082224 |
Mice | Stargardt disease model mice | Intraperitoneal injection | 1 mg/kg, 2 mg/kg, 3 mg/kg, 10 mg/kg | Single dose, 30 minutes before light exposure | Evaluate the protective effect of α1-AR antagonists on bright light-induced retinopathy, results showed DOX significantly protected retinal morphology and function | PMC3859412 |
CD-1 mice | Paracetamol-induced hepatotoxicity model | Intraperitoneal injection | 35.7 mmol/kg | Single dose, 1 hour before paracetamol | To evaluate the protective effect of doxazosin against paracetamol-induced hepatotoxicity. Results showed that doxazosin significantly reduced serum ALT activity, indicating hepatoprotective effects. | PMC2259197 |
C57BL/6 mice | Carbon tetrachloride (CCl4)-induced mouse liver fibrosis model | Gavage | 2.5, 5, 10 mg/(kg*day) | Once daily for 20 weeks | Doxazosin improved the survival rates of CCl4-induced mice and alleviated pathological damage associated with liver fibrosis. | PMC8387324 |
Zebrafish larvae | Adgrl3.1 mutant model | System water | 0.1 µM, 1 µM, 10 µM, 30 µM, 100 µM | Single administration, 1 hour before recording | To evaluate the rescue effect of Doxazosin on the hyperactive phenotype of adgrl3.1 mutant zebrafish larvae. Results showed that all tested doses significantly reduced the average distance moved in mutant larvae. | PMC10267219 |
Clinical Trial:
NCT Number | Conditions | Phases | Recruitment | Completion Date | Locations |
NCT00285519 | Hypertension | Phase 4 | Completed | - | Japan ... More >> Division of Cardiovascular Medicine, Department of Medicine, Jichi Medical University School of Medicine Shimotsuke, Tochigi, Japan, 329-0498 Less << |
NCT00295542 | Hypertension | Phase 4 | Completed | - | Spain ... More >> Hospital Clinico Universitario Santiago de Compostela, Spain, 15706 Less << |
NCT00741585 | Essential Hypertension ... More >> Cardiovascular Disease Stroke Chronic Kidney Disease Less << | Phase 4 | Completed | - | Spain ... More >> CS Friol Friol, Lugo, Spain, 27220 CS Baiona Baiona, Pontevedra, Spain, 36300 CS Bueu Bueu, Pontevedra, Spain, 36930 CS A Estrada La Estrada, Pontevedra, Spain, 26680 CS A Guarda La Guardia, Pontevedra, Spain, 36780 CS Valmiñor Nigran, Pontevedra, Spain, 36250 CS Panxón Nigrán, Pontevedra, Spain, 36340 CS Tomiño Tomiño, Pontevedra, Spain, 36200 Bioengineering & Chronobilogy Labs., University of Vigo Vigo, Pontevedra, Spain, 36200 Hospital do Meixoeiro Vigo, Pontevedra, Spain, 36200 CS Calle Cuba Vigo, Pontevedra, Spain, 36202 CS A Doblada Vigo, Pontevedra, Spain, 36205 CS Coia Vigo, Pontevedra, Spain, 36209 CS Sardoma Vigo, Pontevedra, Spain, 36214 CS Teis Vigo, Pontevedra, Spain, 36216 CS Vilaboa Vilaboa, Pontevedra, Spain, 36141 CS San Roque Vilagarcía De Arousa, Pontevedra, Spain, 36600 CS Fingoi Lugo, Spain, 27002 Complexo Hospitalario Universitario de Ourense Orense, Spain, 32005 CS Lerez Pontevedra, Spain, 36156 Less << |
NCT00004266 | Diabetic Nephropathy | Phase 3 | Completed | - | United States, Minnesota ... More >> Hennepin County Medical Center Minneapolis, Minnesota, United States, 55415 Less << |
NCT00661895 | Hypertension | Phase 4 | Completed | - | United States, Nebraska ... More >> Creighton Community Health Center Omaha, Nebraska, United States, 68104 Less << |
NCT00563901 | - | Completed | - | United States, Minnesota ... More >> University of Minnesota Minneapolis, Minnesota, United States, 55455 United States, Texas University of Texas Houston Houston, Texas, United States, 77030 Less << | |
NCT00000522 | Cardiovascular Diseases ... More >> Heart Diseases Hypertension Vascular Diseases Less << | Phase 2 | Completed | - | - |
NCT00661895 | - | Completed | - | - | |
NCT01323998 | - | Completed | - | - | |
NCT00535925 | Diabetic Nephropathy | Phase 4 | Unknown | September 2012 | Italy ... More >> Department of Clinical and Experimental Medicine, Second University of Naples Naples, Italy, I-80131 Less << |
NCT01323998 | - | Completed | - | - | |
NCT01819220 | Hypertension | Phase 4 | Completed | - | Korea, Republic of ... More >> Yonsei universty medical center Seoul, Korea, Republic of, 120-752 Less << |
NCT00684489 | Hypertension | Not Applicable | Completed | - | - |
NCT00000542 | Cardiovascular Diseases ... More >> Coronary Disease Diabetes Mellitus Heart Diseases Hypercholesterolemia Hypertension Myocardial Infarction Myocardial Ischemia Heart Failure Less << | Phase 3 | Completed | - | - |
NCT01332487 | - | Completed | - | - | |
NCT01332435 | - | Completed | - | - | |
NCT01332487 | - | Completed | - | - | |
NCT01386983 | - | Completed | - | - | |
NCT00141596 | Hypertension | Not Applicable | Terminated(Insufficient accrua... More >>l rate) Less << | - | United Kingdom ... More >> Blood Pressure Unit, Dept. Cardiac & Vascular Sciences, SGUL London, United Kingdom, SW17 0RE Less << |
NCT01390870 | - | Completed | - | - | |
NCT01332435 | - | Completed | - | - | |
NCT01435954 | - | Completed | - | - | |
NCT00424801 | Microvascular Angina ... More >> Hypertension Less << | Not Applicable | Terminated(Due to recent findi... More >>ngs relating MRI contrast to nephrogenic systemic fibrosis) Less << | December 2008 | Denmark ... More >> Aarhus Hospital Aarhus, Denmark, 8000 Less << |
NCT01589484 | Urolithiasis ... More >>Urinary Lithiasis Kidney Calculi Less << | Not Applicable | Completed | - | Brazil ... More >> University of Sao Paulo Sao Paulo, SP, Brazil Less << |
NCT01589484 | - | Completed | - | - | |
NCT01386983 | - | Completed | - | - | |
NCT00687388 | Benign Prostatic Hyperplasia | Phase 4 | Withdrawn(in order to prepare ... More >>a new clinical trial to evaluate with pathological change) Less << | - | Korea, Republic of ... More >> Severance Hospital Seoul, Korea, Republic of, 120-752 Samsung Medical Center Seoul, Korea, Republic of, 135-710 Asan Medical Center Seoul, Korea, Republic of, 138-736 Less << |
NCT00713739 | Kidney Stones | Phase 3 | Unknown | December 2012 | United States, California ... More >> Naval Medical Center San Diego Recruiting San Diego, California, United States, 92134 Contact: Brian K Auge, M.D. 619-532-7200 Contact: Sean P. Stroup, M.D. 619-532-7200 Principal Investigator: Brian K. Auge, M.D. Principal Investigator: Sean P. Stroup, M.D. Less << |
NCT00006294 | - | Completed | - | United States, Kentucky ... More >> University of Kentucky Lexington, Kentucky, United States, 40536 Less << | |
NCT03043612 | Urolithiasis | Not Applicable | Completed | - | Hong Kong ... More >> Prince of Wales/Chinese University of Hong Kong Sha Tin, Hong Kong Less << |
NCT01661621 | Bladder Outlet Obstruction | Phase 4 | Completed | - | Taiwan ... More >> Buddhist Tzu Chi General Hospital Hualien, Taiwan, 970 Less << |
NCT02266537 | Healthy | Phase 1 | Completed | - | - |
NCT01661621 | - | Completed | - | - | |
NCT01390870 | - | Completed | - | - | |
NCT01798992 | - | Completed | - | - | |
NCT01798992 | Idiopathic Dilated Cardiomyopa... More >>thy Less << | Phase 4 | Completed | - | United States, Colorado ... More >> University of Colorado Hospital Denver, Colorado, United States, 80220 United States, Utah University of Utah Medical Center Salt Lake City, Utah, United States, 84132 Less << |
NCT00021814 | Prostatic Hyperplasia ... More >> Prostatic Hypertrophy, Benign Less << | Phase 3 | Completed | - | United States, California ... More >> University of California La Jolla, California, United States, 92093-0694 United States, Colorado Univ of Colorado Health Sciences Center Aurora, Colorado, United States, 80010-0510 United States, Connecticut Yale University New Haven, Connecticut, United States, 06520 United States, District of Columbia Walter Reed Army Medical Center Washington, District of Columbia, United States, 20307 United States, Georgia Emory University Atlanta, Georgia, United States, 30322 United States, Illinois Northwestern University Chicago, Illinois, United States, 60611 United States, Iowa University of Iowa Hospitals Clinics Iowa City, Iowa, United States, 52242 United States, Maryland University of Maryland Baltimore, Maryland, United States, 21201 United States, Michigan Henry Ford Health Systems Detroit, Michigan, United States, 48202 United States, Minnesota Mayo Foundation Rochester, Minnesota, United States, 55905 United States, Missouri Washington University Saint Louis, Missouri, United States, 63141 United States, New York New York University School of Medicine New York, New York, United States, 10010 Columbia Presbyterian Medical Center New York, New York, United States, 10032 United States, Tennessee Vanderbilt University Nashville, Tennessee, United States, 37232-2765 United States, Texas UT Southwestern Medical Center Dallas, Texas, United States, 5235-9110 Baylor College of Medicine Houston, Texas, United States, 77005 Brooke Army Medical Center San Antonio, Texas, United States, 78234-6200 Less << |
NCT00517179 | Prostatic Hyperplasia ... More >> Impotence Less << | Not Applicable | Completed | - | China ... More >> Prince of Wales Hospital Hong Kong, China Less << |
NCT00645034 | Benign Prostatic Hyperplasia | Phase 2 | Completed | - | United States, California ... More >> Pfizer Investigational Site Laguna Woods, California, United States, 92653 Pfizer Investigational Site Newport Beach, California, United States, 92660 Less << |
NCT00563485 | Prostatic Hyperplasia ... More >> Urinary Retention Less << | Not Applicable | Terminated | - | China ... More >> Prince of Wales Hospital Hong Kong, China Less << |
NCT00648323 | Prostate | Phase 4 | Completed | - | Taiwan ... More >> Pfizer Investigational Site Kaohsiung, Taiwan, 813 Pfizer Investigational Site Taichung, Taiwan Pfizer Investigational Site Taipei, Taiwan Pfizer Investigational Site Taoyuan, Taiwan Less << |
NCT02538744 | Cocaine Dependence | Phase 1 | Unknown | - | United States, Texas ... More >> Michael Debakey VA Medical Center Recruiting Houston, Texas, United States, 77030 Contact: Thomas Newton, MD 713-791-1414 ext x6498 tnewton@bcm.edu Principal Investigator: Thomas Newton, MD Less << |
NCT00130156 | High Blood Pressure | Phase 4 | Completed | - | Taiwan ... More >> National Taiwan University Hospital. Taipei, Taiwan Less << |
NCT00295555 | Diabetes Mellitus ... More >> Essential Hypertension Renal Failure Less << | Phase 4 | Completed | - | Japan ... More >> Yokohama City University Center Hospital Yokohama, Japan, 232-0024 Less << |
NCT02369081 | Hypertension, Resistant to Con... More >>ventional Therapy Less << | Phase 4 | Unknown | August 2015 | United Kingdom ... More >> NHS Ayrshire Ayrshire, United Kingdom University Hospitals Birmingham NHS Foundation Trust Birmingham, United Kingdom University of Birmingham Birmingham, United Kingdom University of Cambridge - Addenbrookes Hospital Cambridge, United Kingdom, CB2 2QQ NHS Tayside/University of Dundee Dundee, United Kingdom NHS Lothian/University of Edinburgh Edinburgh, United Kingdom Royal Devon & Exeter NHS Foundation Trust Exeter, United Kingdom NHS Greater Glasgow and Clyde/University of Glasgow Glasgow, United Kingdom Ixworth GP Practice Ixworth, United Kingdom University Hospitals of Leicester NHS Trust Leicester, United Kingdom Barts and the London School of Medicine and Dentistry London, United Kingdom Guys and St Thomas' NHS Foundation Trust London, United Kingdom Imperial College Healthcare NHS Trust London, United Kingdom Central Manchester University Hospitals NHS Foundation Trust Manchester, United Kingdom Norfolk and Norwich University Hospital NHS Trust Norwich, United Kingdom West Hertfordshire Hospitals NHS Trust Watford, United Kingdom Less << |
NCT03176693 | Pheochromocytoma ... More >> Paraganglioma Less << | Phase 3 | Recruiting | May 2024 | United States, California ... More >> University of California, Los angeles Recruiting Los Angeles, California, United States, 90025 Principal Investigator: Masha J Livhits, MD Sub-Investigator: Eric J Kuo, MD Less << |
NCT01678313 | - | Completed | - | - | |
NCT01100021 | Erectile Dysfunction | Phase 1 | Completed | - | United States, Arizona ... More >> MDS Pharma Services Inc., Tempe, Arizona, United States, 85283 Less << |
NCT01678313 | Benign Prostatic Hyperplasia | Phase 2 | Completed | - | Taiwan ... More >> Buddhist Tzu Chi General Hospital Hualien, Taiwan, 970 Less << |
NCT02563405 | Hypertension | Phase 2 Phase 3 | Unknown | October 2018 | China, Heilongjiang ... More >> uric acid test and 24-hour ambulatory BP monitoring Recruiting Harbin, Heilongjiang, China, 150001 Contact: Yujiao Pan, MM 86-451-85555671 panyujiao@163.com Less << |
NCT01946035 | Allergic Rhinitis | Phase 4 | Completed | - | United Kingdom ... More >> Brian Lipworth Dundee, United Kingdom, DD1 3AU Less << |
NCT01389609 | Hypertension | Phase 1 | Completed | - | Japan ... More >> Pfizer Investigational Site Shinjuku-ku, Tokyo, Japan Less << |
NCT03415581 | Opioid-use Disorder | Phase 2 | Recruiting | March 30, 2020 | United States, New York ... More >> Jermaine Jones Recruiting Manhattan, New York, United States, 10032 Contact: Jermaine Jones 646-774-6113 jermaine.jones@NYSPI.Columbia.edu Principal Investigator: Sandra D Comer, PhD Less << |
NCT02785393 | Substance-Related Disorders | Phase 1 | Completed | - | United States, Texas ... More >> Michael Debakey VA Medical Center Houston, Texas, United States, 77030 Less << |
NCT01953432 | Cocaine Dependence | Phase 2 | Completed | - | United States, Texas ... More >> Michael E. DeBakey VA Medical Center, Houston, TX Houston, Texas, United States, 77030 Less << |
NCT00730418 | Benign Prostatic Hyperplasia | Not Applicable | Completed | - | Korea, Republic of ... More >> Samsung Medical Center SEoul, Korea, Republic of, 135-710 Less << |
NCT02308202 | PTSD | Phase 1 | Recruiting | December 31, 2018 | United States, Texas ... More >> Baylor College of Medicine Recruiting Houston, Texas, United States, 77030 Less << |
NCT01371851 | Methamphetamine or Cocaine Dep... More >>endence Less << | Phase 1 Phase 2 | Completed | - | United States, Arkansas ... More >> UAMS Psychiatric Research Institute Little Rock, Arkansas, United States, 72205 Less << |
NCT00922506 | Overactive Bladder ... More >> Benign Prostatic Hyperplasia Less << | Phase 4 | Unknown | November 2015 | Korea, Republic of ... More >> Samsung Medical Center Recruiting Seoul, Korea, Republic of, 135-710 Contact: Kyu-Sung Lee, Ph.D 82-2-3410-3554 ksleedr@skku.edu Principal Investigator: Kyu-Sung Lee, Ph.D Less << |
NCT00646841 | Hypertension | Phase 4 | Completed | - | Italy ... More >> Pfizer Investigational Site Brescia, Italy, 25123 Pfizer Investigational Site Monza (Milan), Italy, 20052 Pfizer Investigational Site Padova, Italy, 35128 Spain Pfizer Investigational Site Palamos, Gerona, Spain, 17230 Pfizer Investigational Site Madrid, Spain, 28041 United Kingdom Pfizer Investigational Site London, United Kingdom, EC1M 6BQ Less << |
NCT01379898 | Pheochromocytoma | Phase 4 | Completed | - | Netherlands ... More >> Department of Endocrinology, University Medical Center Groningen Groningen, Netherlands, 9700 RB Less << |
NCT02901977 | Hypertension | Phase 4 | Completed | - | Sweden ... More >> Karolinska Institutet, Daprtment of Clinical Sciences, Danderyd Hospital, Cardiovascular Research Laboratory Stockholm, Sweden, SE-182 88 Less << |
NCT02989493 | Alcoholism | Phase 2 | Recruiting | December 2020 | United States, Wisconsin ... More >> University of Wisconsin Recruiting Madison, Wisconsin, United States, 53706 Contact: John J Curtin, PhD 608-262-0387 jjcurtin@wisc.edu Principal Investigator: John J Curtin, PhD Less << |
NCT00880997 | Cocaine Dependence | Phase 1 | Completed | - | United States, Texas ... More >> Baylor College of Medicine - Michael E. DeBakey VA Medical Center Houston, Texas, United States, 77030 Less << |
NCT01730846 | - | Completed | - | - | |
NCT01386177 | Mood Disorder ... More >> Substance-Related Disorders Amphetamine-Related Disorders Less << | Phase 1 | Completed | - | Switzerland ... More >> University Hospital Basel Basel, Switzerland, 4031 Less << |
NCT01437046 | Alcohol Dependence ... More >> Anxiety Less << | Phase 2 | Completed | - | United States, Rhode Island ... More >> Brown University Center for Alcohol and Addiction Studies Providence, Rhode Island, United States, 02903 Less << |
NCT01730846 | Smoking | Phase 2 | Completed | - | United States, Connecticut ... More >> Yale Center for Clinical Investigations, Yale University New Haven, Connecticut, United States, 06519 Less << |
NCT01145183 | Cocaine Dependence | Phase 2 | Completed | - | United States, Texas ... More >> Baylor College of Medicine Houston, Texas, United States, 77030 Less << |
NCT02500602 | Posttraumatic Stress Disorder ... More >> Alcohol Use Disorders Less << | Phase 2 | Recruiting | March 1, 2019 | United States, South Carolina ... More >> Ralph H. Johnson VA Medical Center, Charleston, SC Recruiting Charleston, South Carolina, United States, 29401-5799 Contact: Nichole N Mazzulo, MS BA 843-577-5011 ext 7193 nichole.mazzulo@va.gov Principal Investigator: Sudie E. Back, PhD Less << |
NCT03398252 | Alcohol Use Disorder | Phase 1 | Not yet recruiting | January 2021 | United States, Texas ... More >> The University of Texas Health Science Center at Houston Not yet recruiting Houston, Texas, United States, 77030 Contact: Jin Ho Yoon, PhD 713-486-2858 Jin.Ho.Yoon@uth.tmc.edu Less << |
NCT01371851 | - | Completed | - | - | |
NCT01062945 | Cocaine Addiction ... More >> Cocaine Abuse Cocaine Dependence Substance Abuse Less << | Phase 1 | Completed | - | United States, Texas ... More >> Michael Debakey VA Medical Center Houston, Texas, United States, 77030 Less << |
NCT01959022 | Stress Disorders, Post-Traumat... More >>ic Less << | Phase 4 | Completed | - | United States, California ... More >> San Francisco Veterans Affairs Medical Center San Francisco, California, United States, 94121 Less << |
NCT02492334 | PTSD Alcohol ... More >>Use Disorder Less << | Phase 1 Phase 2 | Recruiting | March 2019 | United States, South Carolina ... More >> Addiction Sciences Division-Medical University of South Carolina Recruiting Charleston, South Carolina, United States, 29425 Contact: Megan M Moran-Santa Maria, Ph.D. moranm@musc.edu Contact: Francis M Beylotte, MS 8437922522 ext Beylotte beylott@musc.edu Sub-Investigator: Julianne Flanagan, Ph.D. Principal Investigator: Sudie Back, Ph.D. Less << |
NCT03339258 | Stress Disorders, Post-Traumat... More >>ic Less << | Phase 2 | Recruiting | June 2021 | United States, California ... More >> San Francisco VA Medical Center Recruiting San Francisco, California, United States, 94121 Contact: Andrew Levihn-Coon, B.A. 415-221-4810 ext 23809 andrew.levihn-coon@va.gov Less << |
NCT01003886 | - | Completed | - | - | |
NCT01003886 | - | Completed | - | - |
Bio Calculators | ||||
Preparing Stock Solutions | ![]() |
1mg | 5mg | 10mg |
1 mM 5 mM 10 mM |
1.83mL 0.37mL 0.18mL |
9.13mL 1.83mL 0.91mL |
18.26mL 3.65mL 1.83mL |
|
Dissolving Methods |
in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day; The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound. Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:
|